Published in J Urol on December 13, 2008
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer (2014) 2.26
Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management. Urology (2013) 1.51
Contemporary clinical epidemiology of renal cell carcinoma: insight from a population based case-control study. J Urol (2010) 1.23
Developments in the surgical management of sporadic synchronous bilateral renal tumours. BJU Int (2009) 0.81
Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 year follow up. PLoS One (2014) 0.81
Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients? Onco Targets Ther (2014) 0.78
Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma. J Cancer Res Clin Oncol (2015) 0.77
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol (2009) 0.75
Results of laparoscopic cryoablation in the treatment of small renal masses. Indian J Urol (2011) 0.75
[Renal cell carcinoma in older and geriatric patients]. Urologe A (2017) 0.75
Tubulocystic renal cell carcinoma: a new radiological entity. Eur Radiol (2015) 0.75
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer (2007) 2.00
Death certification errors at an academic institution. Arch Pathol Lab Med (2005) 1.82
Attribution of deaths following cancer treatment. J Natl Cancer Inst (2002) 1.63
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol (2005) 1.38
Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol (2004) 1.36
Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol (2006) 1.36
The statistical comparison of relative survival rates. Biometrics (1983) 1.34
Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol (2005) 1.33
Renal tumors in young adults. J Urol (2004) 1.10
Sporadic renal cell carcinoma in young adults: presentation, treatment, and outcome. Urology (2002) 1.06
Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology (2004) 1.01
Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol (2007) 0.99
Association between age and clinical characteristics of renal cell carcinoma in adult patients. Int J Urol (2006) 0.91
Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer (2005) 0.82
A national evaluation of the effect of trauma-center care on mortality. N Engl J Med (2006) 9.74
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol (2009) 6.71
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol (2006) 3.88
Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol (2008) 3.46
Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol (2009) 3.38
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
Cutaneous metastases from genitourinary malignancies. Urology (2004) 2.97
Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol (2011) 2.87
Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg (2009) 2.79
Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer (2008) 2.75
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Academic ranking score: a publication-based reproducible metric of thought leadership in urology. Eur Urol (2011) 2.51
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology (2011) 2.20
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys (2005) 2.08
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer (2011) 1.98
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. Stat Sci (2009) 1.92
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control (2010) 1.69
Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer (2008) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol (2012) 1.64
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Enhancing renal masses with zero net growth during active surveillance. J Urol (2007) 1.59
Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys (2005) 1.57
Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc (2010) 1.56
Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol (2002) 1.48
Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. BJU Int (2014) 1.47
Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology (2011) 1.46
Robot-assisted partial nephrectomy: a large single-institutional experience. Urology (2010) 1.45
Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses. Can J Urol (2012) 1.45
Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol (2010) 1.44
Cancer patient preferences for quality and length of life. Cancer (2008) 1.43
Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. BJU Int (2013) 1.41
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work. Med Care (2015) 1.41
Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol (2013) 1.40
Enhancing renal tumors in patients with prior normal abdominal imaging: further insight into the natural history of renal cell carcinoma. J Urol (2012) 1.40
Outpatient perineal sling in adolescent boys with neurogenic incontinence. J Urol (2009) 1.39
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy. Can J Urol (2017) 1.39
How Hugh Hampton Young's treatment of President Woodrow Wilson's urinary retention and urosepsis affected the resolution of World War I. J Urol (2011) 1.38
The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer (2004) 1.38
Atomic bomb survivor cataract surgery prevalence data are consistent with non-zero threshold dose--Comment on article by Nakashima et al. 2013. Health Phys (2014) 1.38
Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol (2008) 1.37
Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) (2009) 1.36
Open partial nephrectomy for tumor in a solitary kidney: experience with 400 cases. J Urol (2006) 1.35
The National Study on Costs and Outcomes of Trauma. J Trauma (2007) 1.34
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int (2011) 1.31
The impact of trauma-center care on functional outcomes following major lower-limb trauma. J Bone Joint Surg Am (2008) 1.31
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol (2004) 1.26
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J Natl Compr Canc Netw (2009) 1.25
Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines. J Urol (2007) 1.24
Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol (2006) 1.23
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
A preliminary investigation of the predictors of tanning dependence. Am J Health Behav (2008) 1.22
The impact of breast reconstruction on the delivery of chemotherapy. Cancer (2010) 1.20
Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol (2012) 1.19
Contemporary management of small renal masses. Eur Urol (2011) 1.19
Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer (2007) 1.18
A review of contemporary data on surgically resected renal masses--benign or malignant? Urology (2013) 1.15
The effect of age on delay in diagnosis and stage of breast cancer. Oncologist (2012) 1.15
Visual acuity change and mortality in older adults. Invest Ophthalmol Vis Sci (2005) 1.13
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13
Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res (2008) 1.12
Predicting growth of solid renal masses under active surveillance. Urol Oncol (2008) 1.11